The launch of the Retatrutide vial represents a notable shift in the landscape to weight control . This innovative therapy combines two distinct mechanisms – activation of the GLP-1 site and blocking of the DPP-4 enzyme – offering a different method for addressing excess weight . Early research findings suggest promising results in facilitating